HemaSphere, 2572-9241


Related Publications
  1. Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next?

    Gribben, J. G., de Vries, E., Cherny, N. I. & Sonneveld, P., Apr-2020, In : HemaSphere. 4, 2, 2 p., 354.

    Research output: Contribution to journalEditorialAcademicpeer-review

  2. Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

    Wester, R., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Asselbergs, E., de Weerdt, O., Minnema, M. C., Lonergan, S., Palumbo, A., Broijl, A. & Sonneveld, P., Aug-2020, In : HemaSphere. 4, 4, 3 p., e370.

    Research output: Contribution to journalLetterAcademicpeer-review

  3. Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study

    Morello, L., Rattotti, S., Giordano, L., Jerkeman, M., van Meerten, T., Krawczyk, K., Moita, F., Marino, D., Ferrero, S., Szymczyk, M., Aurer, I., El-Galaly, T. C., Di Rocco, A., Visco, C., Carli, G., Defrancesco, I., Carlo-Stella, C., Dreyling, M., Santoro, A. & Arcaini, L., Feb-2020, In : HemaSphere. 4, 1, 6 p., 302.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (3) »

ID: 132904055